Clinical Trials Directory

Trials / Completed

CompletedNCT04080596

DDI Study to Investigate the Impact of Itraconazole on the Pharmacokinetics of Dorzagliatin

A Single Dose, Open Label, Drug-drug Interaction Study to Investigate the Pharmacokinetics, Pharmadynamics and Safety of HMS5552 Administered Alone or in Combination With Itraconazole in Patients With Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
18 (actual)
Sponsor
Hua Medicine Limited · Industry
Sex
All
Age
30 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the impact of itraconzaole on the pharmacokinetics of Dorzagliatin.

Conditions

Interventions

TypeNameDescription
DRUGDorzagliatinGKA for T2DM currently under clinical development

Timeline

Start date
2017-10-13
Primary completion
2017-12-05
Completion
2017-12-05
First posted
2019-09-06
Last updated
2019-09-06

Locations

1 site across 1 country: China

Regulatory

Source: ClinicalTrials.gov record NCT04080596. Inclusion in this directory is not an endorsement.